MEDP · Medpace Holdings, Inc.
$588.43
+0.91% last session
End-of-day data · close of 2026-09-11
Market cap
$16B
Enterprise value
$16B
Trailing P/E
34.3
Forward P/E
30.2
Dividend yield
—
Beta
1.15
Avg volume
0M
Employees
6K
Daily Change %
0.91%
5 Days Change
-0.84%
10 Days Change
-1.29%
30 Days Change
-3.17%
60 Days Change
8.93%
Month to Day Change
0.53%
Year to Day Change
4.39%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MEDP
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-24
Latest call per bank · past 12 months
RBC Capital
Outperform$692
+18.7% vs priceJefferies
Hold$515
-11.7% vs priceBarclays
Equal-Weight$450
-22.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-24 | Mizuho | Maintains | Outperform | $586 → $665 |
| 2026-07-24 | BMO Capital | Maintains | Market Perform | $400 → $600 |
| 2026-07-24 | Truist Securities | Maintains | Hold | $462 → $609 |
| 2026-07-24 | TD Cowen | Maintains | Hold | $419 → $492 |
| 2026-07-24 | RBC Capital | Maintains | Outperform | $484 → $692 |
| 2026-07-24 | Baird | Maintains | Neutral | $547 → $624 |
| 2026-07-13 | Mizuho | Maintains | Outperform | $495 → $586 |
| 2026-07-08 | Baird | Downgrade | Outperform → Neutral | $477 → $547 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.8% above the 50-day MA ($578.34).
- Price vs 200-day MA: Trading 13.0% above the 200-day MA ($520.70).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-4.22) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($393.42) and high ($620.75).
MEDP Price Chart
Loading chart for MEDP…
Fundamentals
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
More in Diagnostics & Research
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.